|
Evogene Ltd. (EVGN) DCF -Bewertung
IL | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Evogene Ltd. (EVGN) Bundle
Stürzen Sie Ihre Analyse und steigern Sie die Präzision mit unserem (EVGN) DCF -Taschenrechner! Mit authentischen Daten von Evogene Ltd. und anpassbaren Annahmen ermöglichen dieses Tool Sie, wie ein erfahrener Investor prognostizieren, analysieren und value (EVGN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .8 | 1.0 | .9 | 1.7 | 5.6 | 8.6 | 13.0 | 19.8 | 30.0 | 45.6 |
| Revenue Growth, % | 0 | 38.11 | -10.58 | 80.11 | 236.72 | 51.91 | 51.91 | 51.91 | 51.91 | 51.91 |
| EBITDA | -16.0 | -23.2 | -27.8 | -26.9 | -23.2 | -8.6 | -13.0 | -19.8 | -30.0 | -45.6 |
| EBITDA, % | -2120.58 | -2228.65 | -2988.71 | -1607.94 | -411.42 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.8 | 2.7 | 2.2 | 2.6 | 2.6 | 7.6 | 11.6 | 17.6 | 26.8 | 40.7 |
| Depreciation, % | 367.73 | 262.21 | 240.22 | 154.03 | 46.31 | 89.26 | 89.26 | 89.26 | 89.26 | 89.26 |
| EBIT | -18.7 | -25.9 | -30.0 | -29.5 | -25.8 | -8.6 | -13.0 | -19.8 | -30.0 | -45.6 |
| EBIT, % | -2488.31 | -2490.87 | -3228.92 | -1761.97 | -457.73 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 46.9 | 48.2 | 53.9 | 35.4 | 31.1 | 8.6 | 13.0 | 19.8 | 30.0 | 45.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.2 | 2.2 | 1.2 | .8 | .7 | 6.2 | 9.4 | 14.2 | 21.6 | 32.8 |
| Account Receivables, % | 160.69 | 208.46 | 126.24 | 47.94 | 11.9 | 71.97 | 71.97 | 71.97 | 71.97 | 71.97 |
| Inventories | -.9 | -1.4 | .1 | .6 | .1 | -2.7 | -4.0 | -6.1 | -9.3 | -14.1 |
| Inventories, % | -118.73 | -132.6 | 9.89 | 33.79 | 1.35 | -30.99 | -30.99 | -30.99 | -30.99 | -30.99 |
| Accounts Payable | 1.0 | .9 | 1.5 | 1.0 | 1.8 | 6.5 | 9.8 | 14.9 | 22.6 | 34.4 |
| Accounts Payable, % | 132.93 | 82.98 | 157.31 | 61.85 | 31.65 | 75.3 | 75.3 | 75.3 | 75.3 | 75.3 |
| Capital Expenditure | -.9 | -.7 | -.7 | -1.2 | -.8 | -5.6 | -8.5 | -12.9 | -19.7 | -29.9 |
| Capital Expenditure, % | -119.52 | -65.58 | -77.85 | -69.91 | -13.92 | -65.45 | -65.45 | -65.45 | -65.45 | -65.45 |
| Tax Rate, % | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 |
| EBITAT | -17.8 | -23.1 | -27.4 | -26.4 | -23.7 | -7.8 | -11.9 | -18.1 | -27.4 | -41.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.2 | -21.7 | -25.8 | -25.5 | -20.5 | -3.9 | -7.3 | -11.0 | -16.8 | -25.5 |
| WACC, % | 5.86 | 5.72 | 5.77 | 5.72 | 5.78 | 5.77 | 5.77 | 5.77 | 5.77 | 5.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -52.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -26 | |||||||||
| Terminal Value | -690 | |||||||||
| Present Terminal Value | -521 | |||||||||
| Enterprise Value | -573 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | -564 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | -123.41 |
What You Will Receive
- Pre-Filled Financial Model: Evogene Ltd.’s actual data facilitates accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, allowing for multiple applications in detailed forecasting.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Evogene Ltd. (EVGN).
- WACC Analysis Tool: Features a pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Evogene Ltd. (EVGN).
- Interactive Dashboard and Visuals: Graphical representations highlight essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Evogene Ltd. (EVGN) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Evogene Ltd.'s (EVGN) intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Evogene Ltd. (EVGN)?
- Designed for Experts: A sophisticated tool tailored for biotech analysts, investors, and researchers.
- Comprehensive Data: Evogene’s historical and projected financials are preloaded for precision.
- Flexible Modeling: Easily test various scenarios and assumptions to gauge potential outcomes.
- Insightful Results: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Investors: Accurately assess Evogene Ltd.'s (EVGN) fair value to inform investment choices.
- CFOs: Utilize a professional-grade DCF model for comprehensive financial reporting and analysis.
- Consultants: Easily customize the template for client valuation reports related to Evogene Ltd. (EVGN).
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Evogene Ltd.’s (EVGN) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Evogene Ltd.’s (EVGN) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.